Sugi Predict

Sugi Predict / Compounds / SCHEMBL3146829

SCHEMBL3146829

SCHEMBL3146829

Cc1c(Br)ccc2nc(N)sc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.44
▸ MAPT P10636 4/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ GAA P10253 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CYP3A4 P08684 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ HTT P42858 2/20 0.38
▸ SCN4A P35499 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ GFER P55789 2/20 0.37
▸ AXL P30530 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8379060 0.81 MAPT (0.45) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL14099867 0.81 SMN1; SMN2 (0.47) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL25338656 0.78 GAA (0.44) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL3136682 0.78 AXL (0.44) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL30002845 0.78 SMN1; SMN2 (0.44) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL12210717 0.78 SMN1; SMN2 (0.43) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL16829700 0.78 ALDH1A1 (0.37) RAB9AALDH1A1NPC1KMT2A
SCHEMBL28892341 0.78 SMN1; SMN2 (0.44) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL20855167 0.78 SMN1; SMN2 (0.49) SMN1; SMN2MAPTRAB9AALDH1A1GAA
SCHEMBL29682160 0.78 GAA (0.44) SMN1; SMN2MAPTRAB9AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747248-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION Institute of Cancer Research: Royal Cancer Hospital (The) (GB) 2026-05-27 — — EP disclosed
WO-2025022093-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2025-01-30 — — WO disclosed
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 — — US disclosed
CN-111592534-B New compounds 特殊治疗有限公司 2023-06-30 — — CN disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 — — US disclosed
EP-3974413-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2022-03-30 — — EP disclosed
EP-3082786-B1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME (US) 2021-10-27 — — EP disclosed
EP-3828179-A1 CYANOPYRROLIDINES AS DUB MODULATORS Mission Therapeutics Limited (GB) 2021-06-02 — — EP disclosed
WO-2015095256-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-06-25 — — WO disclosed
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
EP-2084162-B1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS INC (US) 2012-09-12 — — EP disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 — — US disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 — — US disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 — — US disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 — — US disclosed
EP-2084162-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-08-05 — — EP disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 SMN1; SMN2 3529/4885MAPT 2227/4885RAB9A 519/4885
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE PIK3CA, PIK3CD, PIK3CB SMN1; SMN2 3464/4885MAPT 4111/4885RAB9A 1046/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 SMN1; SMN2 3529/4885MAPT 2227/4885RAB9A 519/4885
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS MAP3K20, TTK, PRKACB SMN1; SMN2 3606/4885MAPT 1886/4885RAB9A 2145/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 SMN1; SMN2 3600/4885MAPT 2428/4885RAB9A 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.